Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
19.24
-0.37 (-1.89%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cartesian Therapeutics Employees
As of December 31, 2023, Cartesian Therapeutics had 38 total employees, including 37 full-time and 1 part-time employees.
Employees
38
Change
n/a
Growth
n/a
Revenue / Employee
$1,261,526
Profits / Employee
-$7,431,026
Market Cap
494.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
RNAC News
- 4 days ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 26 days ago - Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics: Uncertainty Remains - Seeking Alpha
- 4 months ago - Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - GlobeNewsWire
- 5 months ago - Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results - Seeking Alpha